文献速递结核与非结核分枝杆菌

糖尿病患者中4个月利福喷丁方案治疗结核病的疗效与安全性

Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes.
PubMed 文献 · Emerg Infect Dis · 2025-01-01

研究纳入2516例随机分组受试者,其中181例(7.2%)患糖尿病。在166例糖尿病患者微生物学合格分析组中,对照组不利结局为26.3%(15/57),利福喷丁/莫西沙星组为13.8%(8/58),利福喷丁组为29.4%(15/51);对照组与利福喷丁/莫西沙星组差值为-12.5%(95%CI -27.0%至1.9%),与利福喷丁组差值为3.1%(95%CI -13.8%至20.0%)。利福喷丁/莫西沙星组与对照组安全性相似,作者认为该方案可用于结核病合并糖尿病患者。

要点

  • 糖尿病患者占全部随机受试者的7.2%(181/2516)。
  • 糖尿病患者中利福喷丁/莫西沙星组不利结局最少(13.8%)。
  • 利福喷丁/莫西沙星组与对照组安全性相似。

核心结论

  • 在结核病合并糖尿病患者中,利福喷丁/莫西沙星组不利结局最少且安全。
  • 作者认为利福喷丁/莫西沙星方案可用于结核病合并糖尿病患者。

研究设计与样本

  • 研究为对既往随机试验中糖尿病受试者的探索性分析,共2516例随机分组受试者,其中181例(7.2%)患糖尿病。
  • 微生物学合格分析组中糖尿病患者共166例,对照组57例、利福喷丁/莫西沙星组58例、利福喷丁组51例。

主要发现

  • 微生物学合格分析组中,对照组不利结局为26.3%(15/57),利福喷丁/莫西沙星组为13.8%(8/58),利福喷丁组为29.4%(15/51)。
  • 对照组与利福喷丁/莫西沙星组不利结局比例差值为-12.5%(95%CI -27.0%至1.9%)。
  • 对照组与利福喷丁组不利结局比例差值为3.1%(95%CI -13.8%至20.0%)。
  • 利福喷丁/莫西沙星组与对照组安全性结局相似。

临床怎么用

  • 作者认为利福喷丁/莫西沙星方案可用于结核病合并糖尿病患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A previous study demonstrated noninferior efficacy of 4-month rifapentine/moxifloxacin regimen for tuberculosis (TB) treatment compared with the standard regimen. We explored results among study participants with diabetes. Among 2,516 randomized participants, 181 (7.2%) had diabetes. Of 166 participants with diabetes in the microbiologically eligible analysis group, 26.3% (15/57) had unfavorable outcomes in the control regimen, 13.8% (8/58) in the rifapentine/moxifloxacin regimen, and 29.4% (15/51) in the rifapentine regimen. The difference in proportion of unfavorable outcomes between the control and rifapentine/moxifloxacin arms in the microbiologically eligible analysis group was -12.5% (95% CI -27.0% to 1.9%); the difference between the control and rifapentine arms was 3.1% (95% CI -13.8% to 20.0%). Safety outcomes were similar in the rifapentine/moxifloxacin regimen and control arms. Among participants with TB and diabetes, the rifapentine/moxifloxacin arm had fewest unfavorable outcomes and was safe. Our findings indicate that the rifapentine/moxifloxacin regimen can be used in persons with TB and diabetes.

来源:Emerg Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kurbatova EV, Whitworth WC, Peddareddy LP, et al. Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes. Emerg Infect Dis. 2025. PMID: 40023788. doi:10.3201/eid3103.241634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。